TY  - GEN
AU  - Dupuis-Girod,Sophie
AU  - Ginon,Isabelle
AU  - Saurin,Jean-Christophe
AU  - Marion,Denis
AU  - Guillot,Elsa
AU  - Decullier,Evelyne
AU  - Roux,Adeline
AU  - Carette,Marie-France
AU  - Gilbert-Dussardier,Brigitte
AU  - Hatron,Pierre-Yves
AU  - Lacombe,Pascal
AU  - Lorcerie,Bernard
AU  - Rivière,Sophie
AU  - Corre,Romain
AU  - Giraud,Sophie
AU  - Bailly,Sabine
AU  - Paintaud,Gilles
AU  - Ternant,David
AU  - Valette,Pierre-Jean
AU  - Plauchu,Henri
AU  - Faure,Frédéric
TI  - Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output
SN  - 1538-3598
PY  - 2012///0312
KW  - Angiogenesis Inhibitors
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Arteriovenous Malformations
KW  - etiology
KW  - Bevacizumab
KW  - Cardiac Output
KW  - drug effects
KW  - Epistaxis
KW  - Female
KW  - Heart Failure
KW  - Humans
KW  - Liver
KW  - blood supply
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Telangiectasia, Hereditary Hemorrhagic
KW  - complications
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1001/jama.2012.250
ER  -